Castleark Management LLC Grows Position in Krystal Biotech, Inc. $KRYS

Castleark Management LLC raised its stake in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) by 8.1% during the 1st quarter, Holdings Channel.com reports. The fund owned 31,630 shares of the company’s stock after acquiring an additional 2,370 shares during the period. Castleark Management LLC’s holdings in Krystal Biotech were worth $8,171,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. UMB Bank n.a. grew its stake in shares of Krystal Biotech by 34.6% in the 4th quarter. UMB Bank n.a. now owns 144 shares of the company’s stock worth $36,000 after acquiring an additional 37 shares in the last quarter. Optimize Financial Inc boosted its holdings in Krystal Biotech by 1.4% during the fourth quarter. Optimize Financial Inc now owns 2,855 shares of the company’s stock worth $704,000 after purchasing an additional 40 shares during the last quarter. Perigon Wealth Management LLC boosted its holdings in Krystal Biotech by 0.5% during the fourth quarter. Perigon Wealth Management LLC now owns 8,970 shares of the company’s stock worth $2,211,000 after purchasing an additional 41 shares during the last quarter. Regal Investment Advisors LLC grew its position in Krystal Biotech by 1.0% in the 4th quarter. Regal Investment Advisors LLC now owns 4,360 shares of the company’s stock worth $1,075,000 after purchasing an additional 44 shares in the last quarter. Finally, Torray Investment Partners LLC grew its position in Krystal Biotech by 0.4% in the 1st quarter. Torray Investment Partners LLC now owns 12,032 shares of the company’s stock worth $3,108,000 after purchasing an additional 47 shares in the last quarter. 86.29% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

KRYS has been the topic of several recent analyst reports. Weiss Ratings cut shares of Krystal Biotech from a “buy (b)” rating to a “buy (b-)” rating in a research report on Wednesday, July 1st. Evercore reaffirmed an “outperform” rating and issued a $300.00 target price on shares of Krystal Biotech in a report on Tuesday, May 5th. TD Cowen increased their price target on Krystal Biotech from $306.00 to $403.00 and gave the company a “buy” rating in a research report on Thursday, June 18th. Jefferies Financial Group reiterated a “buy” rating and set a $474.00 price target on shares of Krystal Biotech in a report on Monday, July 13th. Finally, Wall Street Zen cut Krystal Biotech from a “buy” rating to a “hold” rating in a research report on Saturday, June 20th. Ten equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $360.67.

Krystal Biotech Stock Performance

Shares of NASDAQ KRYS opened at $335.19 on Monday. The stock has a fifty day simple moving average of $333.77 and a two-hundred day simple moving average of $292.86. Krystal Biotech, Inc. has a 1-year low of $130.50 and a 1-year high of $382.54. The firm has a market cap of $9.88 billion, a price-to-earnings ratio of 44.81 and a beta of 0.50.

Krystal Biotech (NASDAQ:KRYS) last issued its earnings results on Monday, May 4th. The company reported $1.83 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.45 by $0.38. Krystal Biotech had a return on equity of 19.25% and a net margin of 53.92%.The firm had revenue of $116.36 million for the quarter, compared to analyst estimates of $112.11 million. Analysts forecast that Krystal Biotech, Inc. will post 7.31 EPS for the current year.

Insider Activity

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the company’s stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $308.11, for a total transaction of $7,702,750.00. Following the sale, the insider directly owned 1,378,155 shares of the company’s stock, valued at $424,623,337.05. This represents a 1.78% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP John Charles Thomas sold 1,000 shares of the stock in a transaction dated Thursday, June 25th. The stock was sold at an average price of $347.27, for a total transaction of $347,270.00. Following the transaction, the executive vice president owned 1,000 shares of the company’s stock, valued at $347,270. This represents a 50.00% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 26,642 shares of company stock valued at $8,243,923. 13.10% of the stock is currently owned by insiders.

About Krystal Biotech

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.